Rezolute, Inc. (RZLT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Rezolute, Inc. (RZLT) Healthcare & Pipeline Overview

Rezolute, Inc. is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for metabolic diseases, particularly those associated with chronic glucose imbalance. Their lead candidate, RZ358, targets congenital hyperinsulinism, positioning them in the ultra-rare pediatric genetic disorder space.

What Is the Investment Thesis for RZLT?

Rezolute, Inc. presents a focused investment opportunity within the biotechnology sector, driven by its pipeline of clinical-stage assets targeting niche metabolic disorders. The primary value driver is RZ358, currently in Phase 2b trials for congenital hyperinsulinism (CHI). Positive clinical data from this trial could serve as a significant catalyst, potentially leading to accelerated regulatory pathways and eventual commercialization. RZ402, in Phase 1 for diabetic macular edema (DME), offers a secondary growth opportunity, though with a longer development timeline. A potential risk factor is the inherent uncertainty associated with clinical trials and regulatory approvals, as well as the company's reliance on future financing to support ongoing research and development activities. With a market capitalization of $449M and a beta of 0.66, Rezolute exhibits moderate volatility. Successful development and commercialization of RZ358 could substantially increase shareholder value.

Based on FMP financials and quantitative analysis

RZLT Key Highlights

RZ358 is in Phase 2b clinical trials for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

• RZ402, a selective and potent plasma kallikrein inhibitor, is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema.
• Rezolute, Inc. changed its name from AntriaBio, Inc. in December 2017, reflecting a strategic shift in focus.
• The company's market capitalization is $0.33 billion, indicating its current market valuation.
• Rezolute employs 64 individuals, reflecting its scale as a clinical-stage biopharmaceutical company.

Who Are RZLT's Competitors?

RZLT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RZLT's Key Strengths?

Focus on ultra-rare diseases with unmet medical needs.

• Lead product candidate RZ358 in Phase 2b clinical trials.
• Novel mechanism of action for RZ402 in diabetic macular edema (DME).
• Experienced management team with expertise in drug development.

What Are RZLT's Weaknesses?

Clinical-stage company with no currently marketed products.

• Reliance on future financing to support ongoing research and development.
• High risk of clinical trial failure.
• Limited commercial infrastructure.

What Could Drive RZLT Stock Higher?

RZ358 Phase 2b clinical trial data readout for congenital hyperinsulinism.

• RZ402 Phase 1 clinical trial data readout for diabetic macular edema.
• Potential for strategic partnerships and collaborations.
• Regulatory interactions and potential for accelerated approval pathways.

What Are the Key Risks for RZLT?

Negative return on equity (-58.8%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for RZ358 or RZ402.
• Regulatory delays or rejection of marketing applications.
• Competition from established pharmaceutical companies.
• Reliance on future financing to support ongoing research and development.
• Patent challenges and intellectual property disputes.

What Are the Growth Opportunities for RZLT?

• Expansion of RZ358 into additional indications: While currently focused on congenital hyperinsulinism (CHI), RZ358's mechanism of action could potentially be applicable to other metabolic disorders characterized by hyperinsulinemia. Exploring these additional indications would broaden the market opportunity for RZ358 beyond the ultra-rare CHI population. The market size for related hyperinsulinemic conditions is estimated to be substantial, though specific figures require further research. Timeline for expansion would depend on clinical trial results and regulatory considerations.
• Advancement of RZ402 through clinical trials: Successful completion of Phase 1 clinical trials for RZ402 in diabetic macular edema (DME) would pave the way for Phase 2 and Phase 3 studies, potentially leading to regulatory approval and commercialization. The DME market is a significant and growing market, driven by the increasing prevalence of diabetes. Competing therapies include anti-VEGF injections, but RZ402's novel mechanism of action as a plasma kallikrein inhibitor could offer a differentiated approach. Timeline for advancement is dependent on clinical trial outcomes.
• Strategic partnerships and collaborations: Forming partnerships with larger pharmaceutical companies or other biotech firms could provide Rezolute with additional resources, expertise, and funding to accelerate the development and commercialization of its pipeline assets. Such partnerships could also expand the company's geographic reach and market access. The potential value of these partnerships would vary depending on the specific terms and the partner involved. Timeline for establishing partnerships is uncertain but could occur at any stage of development.
• Orphan drug designation and regulatory exclusivity: Securing orphan drug designation for RZ358 in congenital hyperinsulinism (CHI) provides Rezolute with market exclusivity and other regulatory benefits, such as tax credits and reduced regulatory fees. This exclusivity period would protect RZ358 from competition for a specified period, enhancing its commercial potential. The impact of orphan drug designation is significant for ultra-rare diseases, where market size is limited. This is an ongoing benefit assuming continued regulatory compliance.
• Expansion into new therapeutic areas within metabolic diseases: Rezolute could leverage its expertise in metabolic diseases to develop therapies for other related conditions, such as obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). These areas represent significant market opportunities with unmet medical needs. Expansion into these areas would require additional research and development efforts and could involve licensing or acquiring new assets. Timeline for expansion would depend on the specific therapeutic area and the availability of suitable assets.

What Are RZLT's Competitive Advantages?

• Proprietary drug candidates with novel mechanisms of action.
• Orphan drug designation for RZ358 in congenital hyperinsulinism (CHI).
• Strong intellectual property protection for its pipeline assets.
• Expertise in developing therapies for metabolic diseases.

What Does RZLT Do?

Rezolute, Inc., founded in 2010 and headquartered in Redwood City, California, is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. Originally named AntriaBio, Inc., the company rebranded as Rezolute, Inc. in December 2017, marking a strategic shift towards its current focus. The company's primary focus is on developing treatments for conditions characterized by chronic glucose imbalance. Their lead product candidate, RZ358, is a human monoclonal antibody currently in Phase 2b clinical trials for the treatment of congenital hyperinsulinism (CHI), an ultra-rare pediatric genetic disorder where the pancreas secretes too much insulin, leading to severe hypoglycemia. Additionally, Rezolute is developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema (DME), a common complication of diabetes that can lead to vision loss. With a team of 64 employees, Rezolute is dedicated to addressing unmet medical needs in metabolic diseases through innovative therapeutic approaches.

What Products and Services Does RZLT Offer?

• Develop transformative therapies for metabolic diseases.
• Focus on conditions associated with chronic glucose imbalance.
• Lead product candidate RZ358 targets congenital hyperinsulinism (CHI).
• RZ358 is a human monoclonal antibody in Phase 2b clinical trials.
• Developing RZ402 for diabetic macular edema (DME).
• RZ402 is a selective and potent plasma kallikrein inhibitor in Phase 1 clinical trials.

How Does RZLT Make Money?

• Develop and commercialize novel therapeutics for metabolic diseases.
• Focus on ultra-rare and orphan diseases to leverage regulatory advantages.
• Out-license or partner with larger pharmaceutical companies for commercialization.
• Generate revenue through product sales and licensing agreements.

What Industry Does RZLT Operate In?

Rezolute, Inc. operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory hurdles, and substantial investment in research and development. The company focuses on metabolic diseases, a growing area of concern due to the increasing prevalence of diabetes and related complications globally. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms developing therapies for similar indications. Rezolute differentiates itself through its focus on ultra-rare diseases like congenital hyperinsulinism, offering the potential for orphan drug designation and accelerated development pathways. The biotechnology industry is projected to continue growing, driven by advancements in genomics, personalized medicine, and increasing demand for novel therapies.

Who Are RZLT's Key Customers?

• Patients with congenital hyperinsulinism (CHI).
• Patients with diabetic macular edema (DME).
• Healthcare providers who treat these patients.
• Pharmaceutical companies seeking to license or acquire novel therapeutics.

Company Profile

Rezolute, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Nevan Charles Elam. RZLT has traded publicly since 2013.

Rezolute, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 25.02 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Rezolute, Inc. stands at -58.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -64.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -16.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 15.84 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -16.7%, the inverse of the P/E and a quick read on earnings relative to price.

RZLT Valuation & Market Position

With a $449M market cap, Rezolute, Inc. sits in the small-cap segment of the market. Relative to its peer group, RZLT's quantitative score of 54/100 is below the peer average of 83/100.

Wall Street analysts project Rezolute, Inc. revenue of about $386K for fiscal 2026, with EPS near $-0.70. The estimate reflects 6 contributing analysts.

Over the past six months, Rezolute, Inc. insiders filed 7 SEC Form 4 transactions — 6 sales and 1 purchases. On net that is roughly 55K shares disposed (about $193K), a signal worth weighing alongside the fundamentals.

RZLT Financials

RZLT Latest News

RZLT Analyst Consensus

RZLT MoonshotScore

Common Questions About RZLT (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources